GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
Gyre Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Market Cap | $679.10M | $166.30M |
| Enterprise Value | $656.31M | $88.19M |
| PS Ratio | 5.69 | 3.65 |
| PB Ratio | 6.29 | 2.03 |
| P/TBV Ratio | 6.57 | 2.29 |
Enterprise value
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 5.50 | 2.51 |
Income (trailing twelve months)
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Revenue | $119.38M | $58.34M |
| Gross Profit | $112.58M | $105.94M |
| Operating Income | -$16.68M | -$21.40M |
| Pretax Income | -$16.11M | -$14.34M |
| Net Income | -$28.23M | -$22.46M |
| EBITDA | -$13.58M | -$16.91M |
| EPS (Diluted) | -$0.21 | -$0.83 |
Margins
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 94.3% | 52.9% |
| Operating Margin | -14.0% | -44.0% |
| Pretax Margin | -13.5% | -13.3% |
| Profit Margin | -23.6% | -40.2% |
| EBITDA Margin | -11.4% | -30.2% |
| FCF Margin | -5.12% | -9.27% |
Returns
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -28.2% | -53.2% |
| Return on Assets (ROA) | -16.0% | -40.9% |
| Return on Invested Capital (ROIC) | -29.9% | -32.4% |
| Return on Capital Employed (ROCE) | -9.77% | -38.1% |
Growth
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 13.5% | 5.96% |
| Net Income Growth (YoY) | -558.6% | -35.2% |
| Revenue Growth (3Y CAGR) | 4.46% | 2.25% |
| Revenue Growth (5Y CAGR) | 41.0% | 6.48% |
| EPS Growth (3Y CAGR) | -12.6% | -0.17% |
Balance sheet
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $57.35M | $61.43M |
| Net Cash (Debt) | $57.35M | $15.35M |
| Net Cash Per Share | $0.51 | $0.66 |
| Equity (Book Value) | $107.93M | $49.09M |
| Book Value Per Share | $0.97 | $1.37 |
| Tangible Book Value | $103.40M | $23.52M |
| Working Capital | $93.41M | $76.81M |
Financial position
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.26 | 3.34 |
| Quick Ratio | 2.97 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.94M | -$12.35M |
| Capital Expenditures | -$1.17M | -$1.08M |
| Free Cash Flow | -$6.11M | -$20.22M |
| FCF Per Share | -$0.05 | -$0.42 |
Efficiency
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.68 | 0.39 |
| Inventory Turnover | 0.67 | 2.70 |
| Revenue Per Employee | $193.18K | $404.87K |
| Profits Per Employee | -$45.68K | -$703.34K |
| Employee Count | 618 | 74 |
Dividends and yields
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -4.16% | -23.3% |
| FCF Yield | -0.90% | -8.72% |
Shares
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 111,510,000 | 58,127,000 |
| Shares Change (YoY) | 1.20% | 10.9% |
| Shares Change (QoQ) | 16.1% | 0.54% |
| Float | 6,918,320 | 49,136,700 |
| Shares Held by Insiders | 93.8% | 11.6% |
| Shares Held by Institutions | 7.77% | 59.4% |
Taxes
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Income Tax | $3.45M | $79.87K |
Scores
| Measure | Gyre Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 11.78 | -0.22 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -1.87 | -2.62 |
Calculated by StockData from Gyre Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.